IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes

Excerpt from the Press Release:

WOBURN, Mass.–(BUSINESS WIRE)–IM Therapeutics, a clinical-stage company developing first-in-class human leukocyte antigen (HLA)-targeted therapies to treat autoimmune diseases, today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D). The study, a first for the industry, was performed in patients who have a specific genetic trait known as HLA-DQ8, which significantly increases the risk for T1D and is present in the majority of patients. Certain isoforms of genes called HLAs are known to play a strong role in activating autoimmunity in a broad range of autoimmune diseases. IMT-002 is designed to block the HLA-DQ8 isoform and offers the potential for a first-in-class, genetically targeted, orally available medicine to slow down onset or progression of life-threatening T1D.

“We are pleased with the timely completion of the IMT-002 Phase 1b study and the favorable findings on safety and tolerability, the primary study endpoints, in patients with T1D,” said Sarah Bird, Ph.D., Vice President, Clinical Development of IM Therapeutics. “It is also very encouraging that PK profiles and PD readouts have met our expectations as we finalize and execute our plan for an upcoming Phase 2 clinical study.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release